336 related articles for article (PubMed ID: 29030176)
1. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.
Conner TM; Nikolian VC; Georgoff PE; Pai MP; Alam HB; Sun D; Reed RC; Zhang T
Eur J Pharm Sci; 2018 Jan; 111():465-481. PubMed ID: 29030176
[TBL] [Abstract][Full Text] [Related]
2. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.
Conner TM; Reed RC; Zhang T
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522
[TBL] [Abstract][Full Text] [Related]
3. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
Van Matre ET; Cook AM
Neurol Res; 2016 Sep; 38(9):786-91. PubMed ID: 27414414
[TBL] [Abstract][Full Text] [Related]
5. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
6. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
7. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
Reed RC; Dutta S
Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment of epilepsy in elderly people: focus on valproic Acid.
Stephen LJ
Drugs Aging; 2003; 20(2):141-52. PubMed ID: 12534314
[TBL] [Abstract][Full Text] [Related]
9. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
10. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
[TBL] [Abstract][Full Text] [Related]
11. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
Dutta S; Reed RC
Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
[TBL] [Abstract][Full Text] [Related]
12. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
Coupez R; Nicolas JM; Browne TR
Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
[TBL] [Abstract][Full Text] [Related]
14. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
Garikipati V; Toops DS; Fang Q
Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
[TBL] [Abstract][Full Text] [Related]
16. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V
Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480
[TBL] [Abstract][Full Text] [Related]
17. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
[TBL] [Abstract][Full Text] [Related]
18. The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations.
Ahmad AM; Douglas Boudinot F; Barr WH; Reed RC; Garnett WR
Biopharm Drug Dispos; 2005 Dec; 26(9):417-25. PubMed ID: 16216031
[TBL] [Abstract][Full Text] [Related]
19. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
20. Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.
Nakashima H; Oniki K; Nishimura M; Ogusu N; Shimomasuda M; Ono T; Matsuda K; Yasui-Furukori N; Nakagawa K; Ishitsu T; Saruwatari J
PLoS One; 2015; 10(10):e0141266. PubMed ID: 26484865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
